Omale Ugwu I, Ewah Richard L, Amuzie Chidinma I, Ikegwuonu Cordis O, Nkwo Glory E, Iwegbulam Chimaobi C, Ekwuazi Louisa C
Community Medicine, Alex Ekwueme Federal University Teaching Hospital Abakaliki (AEFUTHA), Abakaliki, Nigeria
Anaesthesia, Alex Ekwueme Federal University Teaching Hospital Abakaliki (AEFUTHA), Abakaliki, Nigeria.
BMJ Glob Health. 2025 Apr 2;10(4):e017403. doi: 10.1136/bmjgh-2024-017403.
Vaccine-preventable infectious diseases (VPDs) covered by routine childhood immunisation programmes are major causes of morbidity/mortality as outbreaks continue to reoccur despite repeated efforts to increase immunisation coverage. This trial aimed at increasing optimal/timely immunisation coverage.
The Adaptive Group Intervention for Optimal routine childhood Immunisation Coverage (AGINTOPIC) trial was conducted from 1 June 2022 to 31 May 2023 in Ebonyi state, Nigeria. 16 geographical clusters (where the primary healthcare facilities were providing weekly routine childhood immunisation) were covariate-constrained-randomised (1:1) to control arm (receiving no intervention) and intervention arm (receiving hybrid parents/health workers adaptive engagement to enlighten/facilitate regular communications/working relationships between them regarding optimal immunisation). The primary outcomes included the proportion of children aged 5-9 months who had optimal/timely (cumulative age-appropriate) receipt of every recommended birth to 14 weeks vaccine and the age-appropriate vaccines receipt (receipt timeliness) score. The outcomes were measured via baseline and end-of-study repeated cross-sectional surveys. All analyses were done using a cluster-level method on intention-to-treat basis, and randomisation-based inference was done via adjusted clustered permutation tests (aCPTs) to check the robustness/validity of the main findings.
A mean proportion of 6.0% (SD 8.1) of children aged 5-9 months in the control arm had optimal/timely receipt of every recommended birth to 14 weeks vaccine, vs 14.3% (11.7) in the intervention arm (adjusted prevalence difference 10.8%, 95% CI 0.8% to 20.9%, p=0.0376, aCPT p=0.0093). The mean age-appropriate vaccines receipt score was 75.1 (17.8) in the control arm, vs 85.5 (9.5) in the intervention arm (adjusted mean difference 9.5, 95% CI 1.0 to 17.9, p=0.0317, aCPT p=0.0155).
The AGINTOPIC intervention significantly increased the optimal/timely (cumulative age-appropriate) community-wide routine childhood immunisation coverage, and the evidence illuminates the need for the exploration and adaptation of such pragmatic/dynamic/scalable community engagement intervention by routine childhood immunisation programmes in the global efforts to address the recurrent outbreaks of VPDs.
ISRCTN59811905.
尽管为提高免疫覆盖率做出了反复努力,但疫情仍不断复发,常规儿童免疫计划所涵盖的疫苗可预防传染病(VPDs)仍是发病/死亡的主要原因。本试验旨在提高最佳/及时免疫覆盖率。
最佳常规儿童免疫覆盖率适应性群组干预(AGINTOPIC)试验于2022年6月1日至2023年5月31日在尼日利亚埃邦伊州进行。16个地理集群(其中初级卫生保健机构每周提供常规儿童免疫服务)进行协变量约束随机分组(1:1),分为对照组(不接受干预)和干预组(接受家长/卫生工作者混合适应性参与,以启发/促进他们之间就最佳免疫进行定期沟通/工作关系)。主要结局包括5至9个月大儿童中,从出生到14周龄每剂推荐疫苗均获得最佳/及时(累积年龄适宜)接种的比例,以及年龄适宜疫苗接种(接种及时性)得分。通过基线和研究结束时的重复横断面调查来测量结局。所有分析均采用群组水平方法,基于意向性分析进行,通过调整后的聚类排列检验(aCPT)进行基于随机化的推断,以检验主要发现的稳健性/有效性。
对照组中5至9个月大儿童中,平均有6.0%(标准差8.1%)的儿童从出生到14周龄每剂推荐疫苗均获得最佳/及时接种,而干预组为14.3%(11.7%)(调整后的患病率差异为10.8%,95%置信区间为0.8%至20.9%,p = 0.0376,aCPT p = 0.0093)。对照组的平均年龄适宜疫苗接种得分是75.1(17.8),干预组为85.5(9.5)(调整后的平均差异为9.5,95%置信区间为1.0至17.9,p = 0.0317,aCPT p = 0.0155)。
AGINTOPIC干预显著提高了社区范围内最佳/及时(累积年龄适宜)的常规儿童免疫覆盖率,该证据表明,在全球应对VPDs反复爆发的努力中,常规儿童免疫计划需要探索和采用这种务实/动态/可扩展的社区参与干预措施。
ISRCTN59811905。